Update on Malignant Pleural Mesothelioma

ABSTRACT

Malignant pleural mesothelioma is an aggressive cancer principally attributable to asbestos. Although the incidence is now declining in the United States, it will continue to increase worldwide until all nations institute regulations limiting asbestos use and exposure. This is a heterogeneous disease, with three pathological subtypes that yield very different outcomes. Stage is less important than histology in determining prognosis. The biomarkers serum mesothelin-related peptide and osteopontin are being evaluated for screening asbestos-exposed individuals and monitoring disease response. The optimal surgical procedure remains controversial because extrapleural pneumonectomy and pleurectomy/decortication can achieve similar results. The reference chemotherapy regimen, pemetrexed-cisplatin, improves survival and quality of life. Key questions about maintenance therapy and the optimal regimens for elderly and frail patients remain to be answered. Although few other cytotoxic drugs have activity, a surprising number of novel agents are being investigated.

KEYWORDS

Mesothelioma - asbestos - biomarkers - multimodality - pemetrexed

REFERENCES

• 1 Teta M J, Mink P J, Lau E, Sceurman B K, Foster E D. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates.  Eur J Cancer Prev. 2008;  17 (6) 525-534
• 2 Wagner J C, Sleggs C A, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.  Br J Ind Med. 1960;  17 260-271
• 3 Flores R M, Riedel E, Donington J S et al.. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.  J Thorac Oncol. 2010;  5 (10) 1649-1654
• 4 Hodgson D C, Gilbert E S, Dores G M et al.. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma.  J Clin Oncol. 2007;  25 (12) 1489-1497
• 5 Roushdy-Hammady I, Siegel J, Emri S, Testa J R, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.  Lancet. 2001;  357 (9254) 444-445
• 6 Gee G V, Stanifer M L, Christensen B C et al.. SV40 associated miRNAs are not detectable in mesotheliomas.  Br J Cancer. 2010;  103 (6) 885-888
• 7 Donaldson K, Murphy F A, Duffin R, Poland C A. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma.  Part Fibre Toxicol. 2010;  7 5
• 8 Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.  Am J Epidemiol. 2004;  159 (2) 107-112
• 9 Hodgson J T, McElvenny D M, Darnton A J, Price M J, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.  Br J Cancer. 2005;  92 (3) 587-593
• 10 LaDou J, Castleman B, Frank A et al.. The case for a global ban on asbestos.  Environ Health Perspect. 2010;  118 (7) 897-901
• 11 Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients, I: Diagnosis.  Cancer. 1993;  72 (2) 389-393
• 12 Husain A N, Colby T V, Ordóñez N G et al.. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.  Arch Pathol Lab Med. 2009;  133 (8) 1317-1331
• 13 Rusch V, Giroux D, Edwards J et al.. Initial analyses of the IASLC International Database for Malignant Pleural Mesothelioma (MPM).  [abstract B1.7] Proc IASLC. 2009;  4 (9)
• 14 Herndon J E, Green M R, Chahinian A P, Corson J M, Suzuki Y, Vogelzang N J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.  Chest. 1998;  113 (3) 723-731
• 15 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus P E, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.  J Clin Oncol. 1998;  16 (1) 145-152
• 16 Francart J, Vaes E, Henrard S et al.. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.  Eur J Cancer. 2009;  45 (13) 2304-2311
• 17 Fennell D A, Parmar A, Shamash J et al.. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.  J Clin Oncol. 2005;  23 (1) 184-189
• 18 Gordon G J, Dong L, Yeap B Y et al.. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.  J Natl Cancer Inst. 2009;  101 (9) 678-686
• 19 Butchart E G, Ashcroft T, Barnsley W C, Holden M P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients.  Thorax. 1976;  31 (1) 15-24
• 20 Sugarbaker D J, Strauss G M, Lynch T J et al.. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.  J Clin Oncol. 1993;  11 (6) 1172-1178
• 21 Rusch V W. From the International Mesothelioma Interest Group . A proposed new international TNM staging system for malignant pleural mesothelioma.  Chest. 1995;  108 (4) 1122-1128
• 22 Ray M, Kindler H L. Malignant pleural mesothelioma: an update on biomarkers and treatment.  Chest. 2009;  136 (3) 888-896
• 23 Robinson B W, Creaney J, Lake R et al.. Mesothelin-family proteins and diagnosis of mesothelioma.  Lancet. 2003;  362 (9396) 1612-1616
• 24 Creaney J, Olsen N J, Brims F et al.. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.  Cancer Epidemiol Biomarkers Prev. 2010;  19 (9) 2238-2246
• 25 Creaney J, Yeoman D, Naumoff L K et al.. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.  Thorax. 2007;  62 (7) 569-576
• 26 Wheatley-Price P, Yang B, Patsios D et al.. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma.  J Clin Oncol. 2010;  28 (20) 3316-3322
• 27 Pass H I, Lott D, Lonardo F et al.. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.  N Engl J Med. 2005;  353 (15) 1564-1573
• 28 Park E K, Sandrini A, Yates D H et al.. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.  Am J Respir Crit Care Med. 2008;  178 (8) 832-837
• 29 Creaney J, Yeoman D, Demelker Y et al.. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.  J Thorac Oncol. 2008;  3 (8) 851-857
• 30 Flores R M, Pass H I, Seshan V E et al.. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.  J Thorac Cardiovasc Surg. 2008;  135 (3) 620-626, 626, e1–e3
• 31 Scherpereel A, Astoul P, Baas P European Respiratory Society/European Society of Thoracic Surgeons Task Force et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.  Eur Respir J. 2010;  35 (3) 479-495
• 32 Treasure T, Waller D, Tan C et al.. The mesothelioma and radical surgery randomized controlled trial: the Mars feasibility study.  J Thorac Oncol. 2009;  4 (10) 1254-1258
• 33 Boutin C, Rey F, Viallat J R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy.  Chest. 1995;  108 (3) 754-758
• 34 O'Rourke N, Garcia J C, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.  Radiother Oncol. 2007;  84 (1) 18-22
• 35 Tsao A S, Wistuba I, Roth J A, Kindler H L. Malignant pleural mesothelioma.  J Clin Oncol. 2009;  27 (12) 2081-2090
• 36 Gupta V, Mychalczak B, Krug L et al.. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.  Int J Radiat Oncol Biol Phys. 2005;  63 (4) 1045-1052
• 37 Gupta V, Krug L M, Laser B et al.. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.  J Thorac Oncol. 2009;  4 (6) 746-750
• 38 Allen A M, Czerminska M, Jänne P A et al.. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.  Int J Radiat Oncol Biol Phys. 2006;  65 (3) 640-645
• 39 Weder W, Kestenholz P, Taverna C et al.. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.  J Clin Oncol. 2004;  22 (17) 3451-3457
• 40 Flores R M, Krug L M, Rosenzweig K E et al.. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.  J Thorac Oncol. 2006;  1 (4) 289-295
• 41 Weder W, Stahel R A, Bernhard J Swiss Group for Clinical Cancer Research et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.  Ann Oncol. 2007;  18 (7) 1196-1202
• 42 Rea F, Marulli G, Bortolotti L et al.. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results.  Lung Cancer. 2007;  57 (1) 89-95
• 43 Krug L M, Pass H I, Rusch V W et al.. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.  J Clin Oncol. 2009;  27 (18) 3007-3013
• 44 Van Schil P E, Baas P, Gaafar R European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.  Eur Respir J. 2010;  36 (6) 1362-1369
• 45 Vogelzang N J, Rusthoven J J, Symanowski J et al.. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.  J Clin Oncol. 2003;  21 (14) 2636-2644
• 46 van Meerbeeck J P, Gaafar R, Manegold C European Organisation for Research and Treatment of Cancer Lung Cancer Group et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.  J Clin Oncol. 2005;  23 (28) 6881-6889
• 47 Santoro A, O'Brien M E, Stahel R A et al.. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.  J Thorac Oncol. 2008;  3 (7) 756-763
• 48 Muers M F, Stephens R J, Fisher P MS01 Trial Management Group et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.  Lancet. 2008;  371 (9625) 1685-1694
• 49 Jassem J, Ramlau R, Santoro A et al.. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.  J Clin Oncol. 2008;  26 (10) 1698-1704
• 50 Zalcman G, Margery J, Scherpereel A et al.. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.  [abstract 7020] J Clin Oncol. 2010;  28 (15 Suppl)
• 51 Study of CBP501 + pemetrexed + cisplatin in patients with solid tumors (phase I) and patients with malignant pleural mesothelioma (phase II) .Available at: http://www.clinicaltrials.gov/ct2/results?term=cbp + 501 + mesothelioma Accessed October 10, 2010
• 52 Garland L, Chansky K, Wozniak A et al.. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma.  [abstract 7511] J Clin Oncol. 2009;  27 (15 Suppl)
• 53 Hassan R, Ho M. Mesothelin targeted cancer immunotherapy.  Eur J Cancer. 2008;  44 (1) 46-53
• 54 Kindler H L. Systemic treatments for mesothelioma: standard and novel.  Curr Treat Options Oncol. 2008;  9 (2–3) 171-179
• 55 Anti-TGF monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma .Available at: http://www.clinicaltrials.gov/ct2/results?term=gc1008 + mesothelioma Accessed October 10, 2010
• 56 Anti-TGF monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma .Available at: http://www.clinicaltrials.gov/ct2/results?term=imc + a12 + mesothelioma Accessed October 10, 2010
• 57 Gregorc V, Zucali P A, Santoro A et al.. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.  J Clin Oncol. 2010;  28 (15) 2604-2611
• 58 Everolimus in treating patients with pleural malignant mesothelioma that cannot be removed by surgery .Available at: http://www.clinicaltrials.gov/ct2/results?term=rad + 001 + mesothelioma Accessed October 10, 2010
• 59 Krug L M, Curley T, Schwartz L et al.. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.  Clin Lung Cancer. 2006;  7 (4) 257-261
• 60 Scagliotti G V, Shin D M, Kindler H L et al.. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.  J Clin Oncol. 2003;  21 (8) 1556-1561
• 61 Baas P, Ardizzoni A, Grossi F EORTC Lung Cancer Group et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).  Eur J Cancer. 2003;  39 (3) 353-357
• 62 Wang Y, Zhao R, Chattopadhyay S, Goldman I D. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.  Cancer Res. 2002;  62 (22) 6434-6437
• 63 van den Bogaert D P, Pouw E M, van Wijhe G et al.. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.  J Thorac Oncol. 2006;  1 (1) 25-30
• 64 Ceresoli G L, Zucali P A, Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma.  Cancer Treat Rev. 2010;  36 (1) 24-32
• 65 Bang K, Mazurek J M, Storey E Centers for Disease Control and Prevention (CDC) et al. Malignant mesothelioma mortality—United States, 1999-2005.  MMWR Morb Mortal Wkly Rep. 2009;  58 (15) 393-396
• 66 Castagneto B, Botta M, Aitini E et al.. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).  Ann Oncol. 2008;  19 (2) 370-373
• 67 Ceresoli G L, Zucali P A, Favaretto A G et al.. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.  J Clin Oncol. 2006;  24 (9) 1443-1448
• 68 Ceresoli G L, Castagneto B, Zucali P A et al.. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.  Br J Cancer. 2008;  99 (1) 51-56
• 69 Lee C W, Murray N, Anderson H, Rao S C, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.  Lung Cancer. 2009;  64 (3) 308-313
• 70 Righi L, Papotti M G, Ceppi P et al.. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.  J Clin Oncol. 2010;  28 (9) 1534-1539
• 71 Steele J P, Shamash J, Evans M T, Gower N H, Tischkowitz M D, Rudd R M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma.  J Clin Oncol. 2000;  18 (23) 3912-3917
• 72 La Verde N, Bramati A, Cinquini M et al.. A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM).  [abstract 7040] J Clin Oncol. 2010;  28 (15 Suppl)
• 73 Reck M, Krzakowski M, Jassem J et al.. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM).  [abstract 7507] J Clin Oncol. 2009;  27 (15 Suppl)
• 74 Stebbing J, Powles T, McPherson K et al.. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.  Lung Cancer. 2009;  63 (1) 94-97
• 75 Zucali P A, Ceresoli G L, Garassino I et al.. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.  Cancer. 2008;  112 (7) 1555-1561
• 76 Dubey S, Jänne P A, Krug L et al.. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.  J Thorac Oncol. 2010;  5 (10) 1655-1661
• 77 Nowak A, Millward M, Francis R J et al.. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).  [abstract 7036] J Clin Oncol. 2010;  28 (15 Suppl)
• 78 Karrison T, Kindler H L, Gandara D R et al.. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.  [abstract] J Clin Oncol. 2007;  25 (18 Suppl) 391s
• 79 Krug L M, Dao T, Brown A B et al.. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.  Cancer Immunol Immunother. 2010;  59 (10) 1467-1479